2008 Applied Pharmacoeconomics and Outcomes Research Forum

On Monday I attended the Applied Pharmacoeconomics and Outcomes Research Forum at UCSD.  I will briefly summarize the presentations of the three speakers. Andreas Pleil, Senior Director Worldwide Medical & Outcomes Research, Pfizer.  Dr. Pliel reviewed the findings of International Society For Pharmacoeconomics and Outcomes Research (ISPOR) Task Force on Real World Data.  “Real World” data…

Medicare Part D data available

For researchers interested in studying the Medicare prescription drug benefit, CMS has claims data for Medicare Part D.  Academy Health also has a useful powerpoint presentation giving some more information regarding Medicare Part D and what information is available as part of the CMS Medicare Part D claims data.

How do CDHPs affect Pharmaceutical Spending and Utilization

Recently, health insurers have been more likely to offer a tiered copayment structure to enrollees. Patients face low co-payments for generic drugs, higher copayments for “preferred” name-brand drugs, and the highest for name-brand drugs on a “nonpreferred” list. Consumer driven health plans (CDHPs) however offer a simpler payment system. The consumer generally places funds into…

Lichtenberg says pharmaceuticals increase life expectancy

Frank Lichtenberg has two working papers Lichtenberg (#14008) and Lichtenberg and Duflos (#14009), which show that pharmaceuticals have worked to increase life expectancy. The first paper examines new cardiovascular drugs and finds that new cardiovascular drugs decreased mortality and hospitalizations in OECD countries. If drugs vintage had not increased from 1995-2004: 1) hospitalization and mortality…

Choosing a Medicare Part D plan

As I noted in an earlier post, choosing a Medicare part D plan is difficult.  However, there are resources to help people choose a Medicare Part D plan based on which prescriptions they are taking and where they live.  Medicare has its own Personalized Plan Search.  The private sector also has come up with user-friendly…

Pharmaceutical price increases slowing

Joe Paduda finds the price inflation is slowing for drug purchased through Workers Comp programs. “Drug trend continues to moderate, with inflation in 2007 coming in at 4.3%. That’s a big improvement over last year’s 6.5%, which was a big improvement over the previous year’s 9.5%…” One reason for the price decline may be that…

Pharmaceuticals in Developing Countries

The Economist has an interesting article on how pharmaceutical companies are trying to hawk their wares in developing countries (“Quagmire or goldmine?“) Generally, Pharma has stayed away from selling in developing countries due to uncertainties in their level of patent protection. For instance, Brazil has “threatened to invoke compulsory licensing (a legal mechanism that, in…

Wal-mart: $10 for 90-day supply of generic drugs

Is the free market working?  Looks like.  Wal-mart just dropped its prices on pharmaceuticals.  According to a Marketwatch article (“Wal-mart…“) : Wal-mart will fill prescriptions for as many as 350 generic drugs costing $10 for a 90-day supply Over 1000 over-the-counter drugs are priced at $4 or less.  Many of these include Wal-mart own private…

Increased Copays for high priced drugs

Consumers are starting to pay a larger share for high priced drugs.  According to the N.Y. Times (“Co-payments“), insurance companies “…are charging patients a percentage of the cost of certain high-priced drugs, usually 20 to 33 percent, which can amount to thousands of dollars a month.”  Medicare’s drug plans have introduced new fee schedules where…